Influence of a low‐dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open‐labeled, active‐controlled clinical trial

A 6‐week, randomized, open‐label, active‐controlled clinical trial was conducted to evaluate the influence of a low‐dose curcumagalactomannosides (CGM) (400 mg once daily) in OA subjects. The treatment was compared with a standard combination of 500 mg glucosamine hydrochloride (GLN) and 415 mg chon...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2021-03, Vol.35 (3), p.1443-1455
Main Authors: Thomas, Jestin V., Smina, Thozhuthum Parambil, Khanna, Aman, Kunnumakkara, Ajaikumar B., Maliakel, Balu, Mohanan, Ratheesh, Krishnakumar, Illathu Madhavamenon
Format: Article
Language:English
Subjects:
Active control
Biomedical materials
chondrotin sulphate
Clinical trials
curcumagalactomannoside
curcumin
Curcumin - pharmacology
Curcumin - therapeutic use
Dietary supplements
Dietary Supplements - analysis
Dosage
Female
Glucosamine
Glucosamine - therapeutic use
Humans
Inflammation
Male
Middle Aged
Osteoarthritis
Osteoarthritis, Knee - drug therapy
Pain
phytotherapy
Stiffness
Treatment Outcome
Walking
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 6‐week, randomized, open‐label, active‐controlled clinical trial was conducted to evaluate the influence of a low‐dose curcumagalactomannosides (CGM) (400 mg once daily) in OA subjects. The treatment was compared with a standard combination of 500 mg glucosamine hydrochloride (GLN) and 415 mg chondroitin sulphate (CHN), supplied as a single oral dose twice a day. Out of 84 subjects randomized, 72 subjects who have completed the study were evaluated for the safety and efficacy of the treatments at baseline and subsequent visits (day 28 and 42), by measuring walking performance, VAS, KPS, and WOMAC scores. CGM exhibited 47.02, 21.43, and 206% improvement in VAS, KPS, and walking performance, respectively, compared to the baseline. Similarly, there was 31.17, 32.93, 36.44, and 35% improvement in the pain, stiffness, physical function, and total WOMAC scores. CGM also caused a substantial reduction in the serum inflammatory marker levels. The results indicate that a short‐term supplementation of a low dosage CGM exerted superior beneficial effects than a high‐dosage CHN–GLN combination in alleviating the pain and symptoms of OA subjects. Further clinical trials of extended duration in a larger population is required to substantiate the efficacy of CGM in the long‐term management of OA.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.6907